多组分干预对老年人肉类症无制度化存活期的影响:一项后期分析
Sunghwan Ji1,2, Eunju Lee2, Ji Yeon Baek2
1Department of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Gangnam-gu, Republic of Korea.
Frontiers in medicine
|September 19, 2025
概括
一个24周的干预措施改善了老年人患有肉类症的无医院住院生存率和身体功能. 这一全面的计划增强了弱势群体的独立性,减少了弱势群体的脆弱性.
科学领域:
- 老年学是一门学科.
- 公共卫生 公共卫生
- 老年医学 老年医学
背景情况:
- 肉症显著影响老年人的身体功能和独立性.
- 易受伤害的,社区生活的老年人需要有效的干预措施.
- 多组件干预措施可以解决肉症和脆弱性的多面性.
研究的目的:
- 为了评估24周的综合多元组件干预,老年人与sarcopenia.
- 评估干预对无制度化生存,身体表现和脆弱性的影响.
- 确定干预对弱势群体的长期影响.
主要方法:
- 对前性,非随机干预研究进行后期分析,倾向性得分匹配 (1:1).
- 包括102对相匹配的社区住户老年人患有肉症 (平均年龄~77.6岁,~82%为女性).
- 干预包括运动,营养支持,抑郁症管理,抑郁症,以及在24周内减少家庭危险.
主要成果:
- 干预组显著改善了30个月的无机构住院生存率 (63.4%对照组为87.2%).
- 在短物理性能电池 (SPPB) 评分和步行速度的显著改善在6,18和30个月后被观察到.
- 在6个月后,人们注意到虚弱指数下降,与对照组相比,在以后的时间点上得分相似.
结论:
- 一项为期24周的多组件干预措施显著提高了老年人患有肉类症的长期无住院生存率.
- 干预有效地改善了身体表现,包括SPPB分数和步行速度.
- 这种方法有望提高社会经济脆弱的老年人群的独立性和减少脆弱性.
相关概念视频
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
238
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
238
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
216
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
216